Cel-Sci Corporation (CVM) : Traders are bullish on Cel-Sci Corporation (CVM) as it has outperformed the S&P 500 by a wide margin of 7.17% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 4.03%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 4.08% in the last 1 week, and is up 8.28% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
The stock has recorded a 20-day Moving Average of 5.44% and the 50-Day Moving Average is 5.06%. Cel-Sci Corporation (NYSEMKT:CVM): stock turned positive on Friday. Though the stock opened at $0.491, the bulls momentum made the stock top out at $0.5066 level for the day. The stock recorded a low of $0.49 and closed the trading day at $0.4996, in the green by 0.60%. The total traded volume for the day was 622,906. The stock had closed at $0.4966 in the previous days trading.
The company Insiders own 21.1% of Cel-Sci Corporation shares according to the proxy statements. Institutional Investors own 4.76% of Cel-Sci Corporation shares.
CEL-SCI Corporation is a biotechnology company. The Company is engaged in the research and development of drugs and vaccines. The Company researches and develops immunotherapy products for the treatment of cancer and infectious diseases. The Companys product pipeline consists of Multikine (Leukocyte Interleukin, Injection) investigational immunotherapy against cancer and Human Papilloma Virus (HPV), and Ligand Epitope Antigen Presentation System (LEAPS) technology, with two investigational therapies, LEAPS-H1N1-DC pandemic flu treatment for hospitalized patients, and CEL-2000, a rheumatoid arthritis treatment vaccine. The Companys lead investigational therapy Multikine is in the Phase III clinical trial against head and neck cancer, for which the Company has received Orphan Drug Status from the United States Food and Drug Administration. LEAPS is the Companys pre-clinical technology.